Failure of Tafamidis to Halt Progression of Ala36Pro TTR Oculomeningovascular Amyloidosis

Fabrizio Salvi, Roberto Volpe, Francesca Pastorelli, Andrea Bianchi, Alessandra Vella, Claudio Rapezzi, Mario Mascalchi

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Oculomeningovascular amyloidosis is a variant of transthyretin (TTR) amyloidotic polyneuropathy, which is associated with blindness and brain ischemia, microhemorrages, and siderosis due to prominent production of the abnormal TTR in the eye and in the choroid plexuses. Tafamidis is a TTR stabilizer that is orally administered and, by interfering with amyloid fibril formation and deposition, is capable of slowing progression of TTR polyneuropathy and of early-stage cardiomyopathy. However, the ocular manifestations of amyloid deposition progressed despite tafamidis therapy in Val30Met TTR amyloidosis, and the effects of tafamidis on meningovascular amyloidosis are unknown. We observed failure of tafamidis to halt progression of oculomeningovascular amyloid deposition in a patient with familial Ala36Pro TTR amyloidosis. She received molecular diagnosis at age 24 and presented at age 26 with paresthesias of the lower limbs and bowel dysfunction. Echography showed minimal amyloid opacities in the corpus vitreum. Treatment with tafamidis meglumine was started. Sixteen months later, she complained of severe headache followed by left hemiparesthesias and numbness lasting 20 minutes. Magnetic resonance imaging showed multiple focal and diffuse hemosiderin deposits compatible with microbleeds and early siderosis. Echography showed a marked increase of “vitreal opacities.” Our observation confirms that tafamidis fails in halting increase of vitreal amyloid deposits and indicates that it is presumably ineffective in preventing clinical onset due to progression of meningovascular amyloidosis. These failures may be due to the incapability of tafamidis to cross the blood–retina and blood–brain barriers. Therapeutic options targeting oculomeningovascular TTR amyloidoses in humans are required.

Original languageEnglish
Pages (from-to)e212-e214
JournalJournal of Stroke and Cerebrovascular Diseases
Volume27
Issue number9
DOIs
Publication statusPublished - Sep 1 2018

Fingerprint

Prealbumin
Amyloid
Amyloidosis
Siderosis
Polyneuropathies
Ultrasonography
Eye Manifestations
Hemosiderin
Choroid Plexus
Hypesthesia
Paresthesia
Amyloid Plaques
Blindness
tafamidis
Amyloidosis, Hereditary, Transthyretin-Related
Brain Ischemia
Cardiomyopathies
Headache
Lower Extremity
Therapeutics

Keywords

  • corpus vitreum
  • microhemorrages
  • sideroris
  • Transthyretin

ASJC Scopus subject areas

  • Surgery
  • Rehabilitation
  • Clinical Neurology
  • Cardiology and Cardiovascular Medicine

Cite this

Failure of Tafamidis to Halt Progression of Ala36Pro TTR Oculomeningovascular Amyloidosis. / Salvi, Fabrizio; Volpe, Roberto; Pastorelli, Francesca; Bianchi, Andrea; Vella, Alessandra; Rapezzi, Claudio; Mascalchi, Mario.

In: Journal of Stroke and Cerebrovascular Diseases, Vol. 27, No. 9, 01.09.2018, p. e212-e214.

Research output: Contribution to journalArticle

Salvi, Fabrizio ; Volpe, Roberto ; Pastorelli, Francesca ; Bianchi, Andrea ; Vella, Alessandra ; Rapezzi, Claudio ; Mascalchi, Mario. / Failure of Tafamidis to Halt Progression of Ala36Pro TTR Oculomeningovascular Amyloidosis. In: Journal of Stroke and Cerebrovascular Diseases. 2018 ; Vol. 27, No. 9. pp. e212-e214.
@article{ca34b3f22a29401cb1471216a1f81019,
title = "Failure of Tafamidis to Halt Progression of Ala36Pro TTR Oculomeningovascular Amyloidosis",
abstract = "Oculomeningovascular amyloidosis is a variant of transthyretin (TTR) amyloidotic polyneuropathy, which is associated with blindness and brain ischemia, microhemorrages, and siderosis due to prominent production of the abnormal TTR in the eye and in the choroid plexuses. Tafamidis is a TTR stabilizer that is orally administered and, by interfering with amyloid fibril formation and deposition, is capable of slowing progression of TTR polyneuropathy and of early-stage cardiomyopathy. However, the ocular manifestations of amyloid deposition progressed despite tafamidis therapy in Val30Met TTR amyloidosis, and the effects of tafamidis on meningovascular amyloidosis are unknown. We observed failure of tafamidis to halt progression of oculomeningovascular amyloid deposition in a patient with familial Ala36Pro TTR amyloidosis. She received molecular diagnosis at age 24 and presented at age 26 with paresthesias of the lower limbs and bowel dysfunction. Echography showed minimal amyloid opacities in the corpus vitreum. Treatment with tafamidis meglumine was started. Sixteen months later, she complained of severe headache followed by left hemiparesthesias and numbness lasting 20 minutes. Magnetic resonance imaging showed multiple focal and diffuse hemosiderin deposits compatible with microbleeds and early siderosis. Echography showed a marked increase of “vitreal opacities.” Our observation confirms that tafamidis fails in halting increase of vitreal amyloid deposits and indicates that it is presumably ineffective in preventing clinical onset due to progression of meningovascular amyloidosis. These failures may be due to the incapability of tafamidis to cross the blood–retina and blood–brain barriers. Therapeutic options targeting oculomeningovascular TTR amyloidoses in humans are required.",
keywords = "corpus vitreum, microhemorrages, sideroris, Transthyretin",
author = "Fabrizio Salvi and Roberto Volpe and Francesca Pastorelli and Andrea Bianchi and Alessandra Vella and Claudio Rapezzi and Mario Mascalchi",
note = "Richiesto CORRIGENDUM per modifica di affiliazione (affiliazione imprecisa).",
year = "2018",
month = "9",
day = "1",
doi = "10.1016/j.jstrokecerebrovasdis.2018.04.033",
language = "English",
volume = "27",
pages = "e212--e214",
journal = "Journal of Stroke and Cerebrovascular Diseases",
issn = "1052-3057",
publisher = "W.B. Saunders Ltd",
number = "9",

}

TY - JOUR

T1 - Failure of Tafamidis to Halt Progression of Ala36Pro TTR Oculomeningovascular Amyloidosis

AU - Salvi, Fabrizio

AU - Volpe, Roberto

AU - Pastorelli, Francesca

AU - Bianchi, Andrea

AU - Vella, Alessandra

AU - Rapezzi, Claudio

AU - Mascalchi, Mario

N1 - Richiesto CORRIGENDUM per modifica di affiliazione (affiliazione imprecisa).

PY - 2018/9/1

Y1 - 2018/9/1

N2 - Oculomeningovascular amyloidosis is a variant of transthyretin (TTR) amyloidotic polyneuropathy, which is associated with blindness and brain ischemia, microhemorrages, and siderosis due to prominent production of the abnormal TTR in the eye and in the choroid plexuses. Tafamidis is a TTR stabilizer that is orally administered and, by interfering with amyloid fibril formation and deposition, is capable of slowing progression of TTR polyneuropathy and of early-stage cardiomyopathy. However, the ocular manifestations of amyloid deposition progressed despite tafamidis therapy in Val30Met TTR amyloidosis, and the effects of tafamidis on meningovascular amyloidosis are unknown. We observed failure of tafamidis to halt progression of oculomeningovascular amyloid deposition in a patient with familial Ala36Pro TTR amyloidosis. She received molecular diagnosis at age 24 and presented at age 26 with paresthesias of the lower limbs and bowel dysfunction. Echography showed minimal amyloid opacities in the corpus vitreum. Treatment with tafamidis meglumine was started. Sixteen months later, she complained of severe headache followed by left hemiparesthesias and numbness lasting 20 minutes. Magnetic resonance imaging showed multiple focal and diffuse hemosiderin deposits compatible with microbleeds and early siderosis. Echography showed a marked increase of “vitreal opacities.” Our observation confirms that tafamidis fails in halting increase of vitreal amyloid deposits and indicates that it is presumably ineffective in preventing clinical onset due to progression of meningovascular amyloidosis. These failures may be due to the incapability of tafamidis to cross the blood–retina and blood–brain barriers. Therapeutic options targeting oculomeningovascular TTR amyloidoses in humans are required.

AB - Oculomeningovascular amyloidosis is a variant of transthyretin (TTR) amyloidotic polyneuropathy, which is associated with blindness and brain ischemia, microhemorrages, and siderosis due to prominent production of the abnormal TTR in the eye and in the choroid plexuses. Tafamidis is a TTR stabilizer that is orally administered and, by interfering with amyloid fibril formation and deposition, is capable of slowing progression of TTR polyneuropathy and of early-stage cardiomyopathy. However, the ocular manifestations of amyloid deposition progressed despite tafamidis therapy in Val30Met TTR amyloidosis, and the effects of tafamidis on meningovascular amyloidosis are unknown. We observed failure of tafamidis to halt progression of oculomeningovascular amyloid deposition in a patient with familial Ala36Pro TTR amyloidosis. She received molecular diagnosis at age 24 and presented at age 26 with paresthesias of the lower limbs and bowel dysfunction. Echography showed minimal amyloid opacities in the corpus vitreum. Treatment with tafamidis meglumine was started. Sixteen months later, she complained of severe headache followed by left hemiparesthesias and numbness lasting 20 minutes. Magnetic resonance imaging showed multiple focal and diffuse hemosiderin deposits compatible with microbleeds and early siderosis. Echography showed a marked increase of “vitreal opacities.” Our observation confirms that tafamidis fails in halting increase of vitreal amyloid deposits and indicates that it is presumably ineffective in preventing clinical onset due to progression of meningovascular amyloidosis. These failures may be due to the incapability of tafamidis to cross the blood–retina and blood–brain barriers. Therapeutic options targeting oculomeningovascular TTR amyloidoses in humans are required.

KW - corpus vitreum

KW - microhemorrages

KW - sideroris

KW - Transthyretin

UR - http://www.scopus.com/inward/record.url?scp=85047096452&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047096452&partnerID=8YFLogxK

U2 - 10.1016/j.jstrokecerebrovasdis.2018.04.033

DO - 10.1016/j.jstrokecerebrovasdis.2018.04.033

M3 - Article

VL - 27

SP - e212-e214

JO - Journal of Stroke and Cerebrovascular Diseases

JF - Journal of Stroke and Cerebrovascular Diseases

SN - 1052-3057

IS - 9

ER -